EU-Startups Funding· David Cendon Garcia·· 3 hours agoSame newsAI Score72
Nouscom raises €120M Series D to advance off-the-shelf cancer immunotherapy
Switzerland’s Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials
AI Overview
Basel-based Nouscom closed an oversubscribed €120 million ($135 million) Series D co-led by M Ventures and Revelation Partners.
Same story, shown in Top Deals《Nouscom raises $135M Series D to test cancer prevention vaccine NOUS-209》
Source:EU-Startups Funding · eu-startups.com